-
Apply for a Hong Kong IPO next month as soon as possible?
Time of Update: 2021-07-25
In this regard, WeDoctor told the Blue Whale Financial reporter that we do not comment on the IPO situation .
At that time, WeDoctor told the Blue Whale Financial reporter that it would not respond temporarily .
-
Libang Instruments selected for 2021 FTSE Russell Global Stock Index
Time of Update: 2021-07-25
The selection of Libang Instruments further shows that the international capital market fully recognizes and pays attention to it.
Libang Instruments has developed from a listed company to a representative, high-growth industry leader and actively recognized by international investors.
-
Ganli Pharmaceutical and International Diabetes Federation established cooperation
Time of Update: 2021-07-25
"The International Diabetes Federation is very pleased to welcome Gan Lee Pharmaceuticals as a partner and support our global initiatives to increase awareness, publicity and education .
-
Zhifei Biotech's 2020 net profit exceeds 3.3 billion yuan, and HPV vaccines grow strongly
Time of Update: 2021-07-25
At the same time, the official WeChat account of the Institute of Microbiology of the Chinese Academy of Sciences said that China's first recombinant protein COVID-19 vaccine jointly developed by it and Zhifei Biological was approved to enter Phase III clinical trials in Pakistan .
-
FDA suspends clinical study of bluebird bio-sickle cell disease gene therapy
Time of Update: 2021-07-25
On February 23, bluebird bio announced that the US FDA has put on hold its LentiGlobin gene therapy clinical trial program for the treatment of sickle cell disease (SCD) .
-
An employee reported a large number of frauds by China Life under his real name
Time of Update: 2021-07-25
Recently, female employees of China Life Heilongjiang reported a large number of frauds by real names .
According to the Qicha APP, the full name of the company involved is the Nenjiang branch of China Life Insurance Co.
-
Cansino performance report: 2020 net loss of 407 million yuan
Time of Update: 2021-07-25
%; the net profit attributable to the owners of the parent company after deducting non-recurring gains and losses was -521,740,300 yuan, an increase of 199.
-
Buchang Pharmaceutical intends to sell 1% of the shares of its subsidiary for 0 yuan
Time of Update: 2021-07-24
After the equity transfer is completed, the company will no longer pay, and Rizhao Sanqi shall bear the obligation of actual paid capital contribution and related legal responsibilities .
-
Xianju Pharmaceutical intends to establish joint ventures with Tsinghua University and other companies to lay out the field of diagnostic testing
Time of Update: 2021-07-24
" with Tsinghua University and Quanxinjili (Ningbo) Biotechnology Partnership (Limited Partnership) .
50% of the registered capital; Quanxinjili (Ningbo) Biotechnology Partnership (Limited Partnership) invested 1.
-
Haoyuan Pharmaceutical is listed on the Science and Technology Innovation Board
Time of Update: 2021-07-24
99 yuan, and the total amount of funds raised was 1.
It is reported that Haoyuan Pharmaceuticals is expected to use the funds raised for the Shanghai R&D center upgrade and construction project, Anhui Haoyuan Biomedical R&D Center construction project, Anhui Haoyuan Biomedical R&D Center construction project with an annual output of 121.
-
Liu Xiangguang, the former general manager of Beijing Tongrentang Co., Ltd., was investigated
Time of Update: 2021-07-24
; From August 2008 to November 2009, he served as Deputy Secretary of the Party Committee and Secretary of the Disciplinary Committee, Chairman of the Labor Union, and Deputy General Manager of Beijing Tongrentang Co.
-
WuXi AppTec releases 2020 annual results bulletin: the company achieved annual revenue of 16.54 billion yuan
Time of Update: 2021-07-24
96 billion yuan attributable to the parent, a year-on-year increase of 59.
6%, achieving an adjusted non-IFRS net profit attributable to the parent company was 3.
57 billion yuan, a year-on-year increase of 48.
57 billion yuan, a year-on-year increase of 48.
-
"Dingdang Kuaiyao" completes US$220 million financing led by TPG Asia Fund
Time of Update: 2021-07-24
On June 8, "Dingdang Kuaiyao" completed a new round of financing, the amount of this round of financing was 220 million US dollars, about 1.
32 billion yuan .
CICC and China Renaissance Capital acted as financial advisors for this round of financing .
-
Nuocheng Jianhua will hold 2020 results conference call on March 29, 2021
Time of Update: 2021-07-24
Conference call information Nuocheng Jianhua will hold a conference call at 9:00 am on March 29th, Beijing time .
After the meeting, participants can visit the investor relations page of Nuocheng Jianhua's official website to listen to the replay online .
-
Hualan Biological releases performance report: 2020 net profit reaches 1.604 billion yuan
Time of Update: 2021-07-24
In 2020, net profit attributable to the parent company was 1.
604 billion yuan, a year-on-year increase of 25%; operating income was 5.
023 billion yuan, a year-on-year increase of 35.
-
Aier Ophthalmology: 2020 net profit of approximately 1.724 billion yuan, an increase of 25.01% year-on-year
Time of Update: 2021-07-24
24%; net profit was 1.
01%; non-net profit was 2.
131 billion yuan, a year-on-year increase of 49.
12%; operating net cash flow increased by 60.
87% year-on-year, A number of operating indicators hit record highs .
-
The first batch of Wuhan-produced inactivated vaccines for the new crown is officially launched, and the annual output can reach 100 million doses
Time of Update: 2021-07-23
Wuhan Institute of Biological Products has built a biosafety workshop for the new crown inactivated vaccine.
It is understood that since July 16, 2020, China Bio-Wuhan has carried out the "New Coronary Inactivated Vaccine Phase III Clinical Trial" in many countries including the United Arab Emirates.
-
Allergan Aesthetics VOLUX Real World Data Research Project Achieves Phased Results
Time of Update: 2021-07-23
In December 2019, Allergan Aesthetics VOLUX® was approved by the Hainan Provincial Drug Administration and the Hainan Provincial Health Commission as a clinically urgently needed medical device in the advanced area of Boao Lecheng, and the team of Professor Li Qingfeng of Orthopedic Surgery of Shanghai Ninth Hospital completed the completion in Boao Super Hospital This is the first domestic injection to improve chin and maxillofacial volume .
-
Qiyu Biological Bispecific Antibody Q-1802 Obtained IND Approval in the United States
Time of Update: 2021-07-23
It has independent intellectual property rights and can simultaneously target PD-L1 and Claudin 18.
On the one hand, Q-1802 can kill tumors through effector cells mediated by Claudin 18.
-
Hengrui Medicine Famitinib Malate Capsules and SHR-1701 Injection Approved Clinically
Time of Update: 2021-07-23
On February 25, Hengrui Pharmaceuticals announced that the company and its subsidiaries received the "Drug Clinical Trial Approval Notice" on famitinib malate capsules and SHR-1701 injection approved and issued by the State Food and Drug Administration.
After inquiries, famitinib malate currently has sorafenib, sunitinib, pezopanib and other similar products approved for marketing at home and abroad .
